Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This Phase 1b study in F508del-CFTR homozygous CF patients is being conducted to assess the
safety of N91115 as the sole cystic fibrosis transmembrane conductance regulator (CFTR)
modulator at doses near the expected therapeutic exposure level in preparation for Phase 2
studies of N91115 added to the CFTR modulator combination lumacaftor/ivacaftor when launched.